Cumulative research on the development of huperzine A -- an alkaloid extract of the plant Huperzia serrata -- as a treatment for Alzheimer’s shows it may have advantages over other AChE inhibitors being used in the U.S. to treat Alzheimer’s Disease (AD), according to early results in a new study from Neuro-Hitech (OTCBB: NHPI), a biopharmaceutical company focused on the development and commercialization of next-generation therapies against proven targets for neurodegenerative diseases. Preclinical studies suggest that the potential advantages of huperzine A include higher blood-brain-barrier penetration, better tolerability and multiple mechanisms of action, including both AChE and NMDA antagonism. Antioxidant and neuroprotective properties may also be useful as a disease-modifying treatment. A Phase II study is currently underway.
